114亿美元!信达与武田达成合作 肿瘤药市场能否迎“王炸”?

21世纪经济报道
Oct 22, 2025

继辉瑞与三生制药之后,创新药商业拓展(BD)再迎百亿美元重磅交易。  10月22日,信达生物宣布与武田制药达成重磅全球战略合作,此次合作旨在联合信达生物在肿瘤免疫(IO)与抗体偶联药物(ADC)的创新研发实力,及武田制药全球肿瘤药物开发的深厚经验,加速信达生物两款后期在研药物的全球开发进程,同时武田制药将获得一款早期研发项目的选择权。  根据公开信息,信达生物与武田制药将在全球范围内共同开发新一代...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10